EMOLLIENT MILK XEMOSE IN THERAPY OF ATOPIC DERMATITIS IN CHILDREN



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Structural and functional damages of the epidermal barrier in patients with atopic dermatitis promote the entry of allergens and development of Th2-type allergic inflammation. Moisturizers containing lipids increase the physiological antiinflammatory effects of topical corticosteroids (TGKS), improve the epidermal barrier and reduce the duration of TGKS using preventing further infringement barrier. To evaluate the clinical efficacy of emollient milk Xemose in children with atopic dermatitis. Materials and methods. We examined 27 children with atopic dermatitis. Children were divided into 2 groups: patients in group 1 (n=14) used emollient milk Xemose twice a day on the skin lesions and limbs in the complex therapy, patients in the 2nd group (n=13) received combined therapy incorporating traditional dampening agents on the basis of lanolin (Unna cream) 3 times daily. All patients underwent measurement of transepidermal water loss (TEWl) (Tewameter TM 300, Multi Probe Adapter MPA 5/9, Courage + Khazaka) and the pH of the skin (Skin-pH-Meter, Multi Probe Adapter MPA 5/9, Courage + Khazaka) before and after 2 weeks of therapy. Results. Patients in groupthat used Xemose milk and children in group with Unna cream after 2 weeks showed a statistically significant decrease of TEWl (p=0,041 and p=0,04, respectively). TEWl was significantly lower in children treated for 2 weeks with milk Xemose (p=0,027) than in children treated with Unna cream. in both groups pH skin surface have not changed (р=0,22 and р=0,22 respectively). Conclusion. Clinical efficacy of milk Xemose as compound improving skin barrier function in children with atopic dermatitis was shown.

Full Text

Restricted Access

About the authors

E T KINDEEVA

Russian National Research Medical University named after N.I. Pirogov

Email: ekindeeva@bk.ru
Moscow

N G KOROTKII

Russian National Research Medical University named after N.I. Pirogov

Moscow

A N PAMPURA

Russian National Research Medical University named after N.I. Pirogov

Moscow

References

  1. Saijic D., Asiniwasis R., Skotnicki-Grant S. A look at epi- dermal barrier function in atopic dermatitis: Physiologic lipid replacement and the role of ceramide. Skin Therapy Lett. 2012, v. 7, р. 6-9.
  2. Boguniewicz M., Leung D.Y. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol. Rev. 2011, v. 242, р. 233-246.
  3. Elias P.M., Wood L.C., Feingold K.R. Epidermal pathogenesis of inflammatory dermatoses. American Journal of Contact Dermatitis. 1999, v. 10, р. 119-126.
  4. Taïeb A. Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact Dermatitis. 1999, v. 41, р. 177-180.
  5. Elias P., Feingold K., Fluhr J. The skin as an organ of protec- tion. In Dermatology in General Medicine. Friedberg I.M., Eisen A.Z., Wolff K. et al. editors. New York. 2003, р. 107-118.
  6. Madison K.C. Barrier function of the skin: «la raison d`etre» of the epidermis. J. Invest. Dermatol. 2003, v. 121, р. 231-241.
  7. Fluhr J.W., Kao J., Jain M. et al. Generation of free fatty acids from phospholipids regulates stratum corneum acidification and integrity. J. Invest. Dermatol. 2001, v. 117, р. 44-51.
  8. Lee Y.B., Park H.J., Kwon M.J. et al. Beneficial effects of pseudoceramide-containing physiologic lipid mixture as a vehicle for topical steroids. Eur. J. Dermatol. 2011, v. 21, р. 710-716.
  9. Sugarman J.L., Parish L.C. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J. Drugs Dermatol. 2009, v. 8, р. 1106-1111.
  10. Elias P.M. Barrier-repair therapy for atopic dermatitis: cor- rective lipid biochemical therapy. Expert Rev. Dermatol. 2008, v. 3, р. 441-452.
  11. Akdis C., Akdis M., Bieber T. et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology. American Academy of Allergy, Asthma and Immunology. PRACTALL Consensus Report. J. Allergy. Clin. Immunol. 2006, v. 118, р. 152-169.
  12. Белоусова Т.А., Горячкина М.В. Современные пред- ставления о структуре и функции кожного барьера и терапевтические возможности коррекции его нарушений. Рус. мед. журн. 2004, № 8, c. 14-18.
  13. Lodén M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am. J. Clin. Dermatol. 2003, v. 4, р. 771-188.
  14. Sato J., Denda M., Chang S. et al. Abrupt decreases in environ- mental humidity induce abnormalities in permeability barrier homeostasis. J. Invest. Dermatol. 2002, v. 119, р. 900-904.
  15. De Benedetto A., Kubo A., Beck L.A. Skin Barrier Disrup- tion - A Requirement for Allergen Sensitization? J. Invest. Dermatol. 2012, v. 132, р. 949-963.
  16. Elias P.M., Ahn S.K., Denda M. et al. Modulations in epider- mal calcium regulate the expression of differentiation-specific markers. J. Invest. Dermatol. 2002, v. 119, р. 1128-1136.
  17. Hachem J.P., Crumrine D., Fluhr J. et al. pH directly regu- lates epidermal permeability barrier homeostasis and stratum corneum integrity cohesion. J. Invest. Dermatol. 2003, v. 121, р. 345-353.
  18. Ramachandran R., Hollenberg M.D. Proteinases and signa- ling: pathophysiological and therapeutic implications via PARs and more. Br. J. Pharmacol. 2008, v. 153. р. 263-282.
  19. Wood L. C., Elias P. M., Calhoun C. et al. Barrier disruption stimulates interleukin-1 alpha expression and release from a pre-formed pool in murine epidermis. J. Invest. Dermatol. 1996, v. 106, р. 397-403.
  20. Elias P.M., Hatano Y., Williams M.L. Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J. Allergy Clin. Immunol. 2008, v. 121, р. 1337-1343.
  21. Mauro T., Holleran W.M., Grayson S. et al. Barrier recovery is impeded at neutral pH, independent of ionic effects: implications for extracellular lipid processing. Arch. Dermatol. Res. 1998, v. 290, р. 215-222.
  22. Ohman H., Vahlquist A. The pH gradient over the stratum corneum differs in X-linked recessive and autosomal dominant ichthyosis: a clue to the molecular origin of the «acid skin mantle»? J. Invest. Dermatol. 1998, v. 111, р. 674-677.
  23. Hachem J.P., Man M.Q., Crumrine D. et al. Sustained serine proteases activity by prolonged increase in pH leads to degra- dation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. J. Invest. Dermatol. 2005, v. 125, р. 510-520.
  24. Hachem J.P., Fowler A., Behne M. et al. Increased stratum corneum pH promotes activation and release of primary cy- tokines from the stratum corneum attributable to activation of serine proteases. J. Invest. Dermatol. 2002, v. 119. р. 258.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2014



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies